Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Liveyon PURE PRO is an unapproved cellular therapy product derived from human umbilical cord blood, containing approximately 30 million live total nucleated cells per dose. Developed by Liveyon Labs and marketed by Liveyon LLC, it was promoted for the treatment of various orthopedic conditions, including back pain, knee pain, and joint degeneration, typically administered via intra-articular injection. The product was claimed to facilitate the regeneration of bone, muscle, and cartilage through the release of reparative growth factors and proteins. In December 2019, the FDA issued a warning letter citing significant manufacturing violations and the lack of a biologics license application (BLA) or investigational new drug (IND) application, leading to the suspension of its sales.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Liveyon PURE PRO.